Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone monotherapy in advanced NSCLC
NCT03693547Phase 2Completed
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Jun 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in non-small cell lung cancer (NSCLC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started Apr 2019; status: completed.
02
Drugs
utidelone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03693547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693547.